Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inadequate response to ustekinumab are limited. This study investigates guselkumab's long-term effectiveness and safety in patients with psoriasis with partial response to ustekinumab.
Methods: We performed a retrospective multicentric study analyzing data of patients with psoriasis from seven Italian hospitals between January 2021 and May 2024. The study included 169 patients who switched from ustekinumab to guselkumab. Primary endpoints were Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and absolute PASI ≤ 2. Site-specific Physician Global Assessment (PGA) scores were also collected for difficult-to-treat areas.
Results: The study included 169 patients. After 3 years of treatment, PASI 75, PASI 90 and PASI 100 were achieved by 88.4%, 55.8%, and 32.6% of patients, respectively. Site-specific PGA showed significant improvements, especially in the scalp and genital areas. After 3 years of treatment, no significant impact of higher body mass index (BMI) or cardiometabolic comorbidities on guselkumab effectiveness was detected. No severe adverse events were reported during the study period.
Conclusions: In our study, guselkumab provided significant long-term effectiveness and safety in patients partially responsive to ustekinumab, improving both PASI score and site-specific PGA and confirming its potential use for patients with psoriasis switching from ustekinumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557789 | PMC |
| http://dx.doi.org/10.1007/s13555-024-01270-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study.
Indian J Dermatol
September 2025
From the Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China.
Background: Overweight and obesity are common in patients with psoriasis and are associated with increased disease severity and declined treatment response.
Aims: To evaluate the short-to-medium term (24w) efficacy and safety of two biologics, including Guselkumab and Secukinumab, in overweight and obese patients (body mass index [BMI] ≥25 kg/m) with moderate to severe psoriasis.
Materials And Methods: We retrospectively analyzed the data of patients with moderate to severe plaque psoriasis treated with Guselkumab or Secukinumab in Dermatology Hospital of Southern Medical University in 2020.
A randomized controlled study protocol to determine the safety and efficacy of Sivanarvembu Kuzhithailam in the management of Psoriasis (Kalanjagapadai).
J Ayurveda Integr Med
September 2025
Research Officer (Siddha), Siddha Regional Research Institute, Puducherry, India.
Background: Psoriasis is a chronic skin disorder with a substantial global burden, affecting over 100 million people worldwide. Conventional treatments, including topical and systemic therapies, have their own limitations and side effects. Siddha medicine, deeply rooted with comprehensive principles, offers an alternative approach in Psoriasis management.
View Article and Find Full Text PDFMRI versus CT before endovascular thrombectomy in the early time window: A systematic review and meta-analysis.
J Neuroradiol
September 2025
Department of Diagnostic and Interventional Neuroradiology, Tours University Hospital, Tours, France; Department of Clinical Neurosciences and Diagnostic Imaging, University of Calgary, AB, Canada; Imaging Brain & Neuropsychiatry, iBrain U1253, INSERM, University of Tours, Tours, France. Electronic
Background: Selection of acute stroke patients for endovascular thrombectomy (EVT) within 6 h from symptom onset can be done using MRI or CT. However, association of either imaging modality with better clinical outcomes or shorter workflow times is still not fully understood.
Methods: We searched Medline and Ovid-Embase for studies comparing outcomes and workflow metrics between patients selected for EVT using CT or MRI from inception to November 30, 2024.
Unveiling the Metabolic Burden: A Clinicopathological Study of Chronic Plaque Psoriasis and Its Association With Metabolic Syndrome.
Cureus
August 2025
Department of Pathology, Mahatma Gandhi Memorial Medical College, Indore, IND.
Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease with systemic manifestations. Among its significant comorbidities, metabolic syndrome (MS) - a constellation of obesity, hypertension, dyslipidemia, and insulin resistance - has gained recognition due to its association with increased cardiovascular risk and reduced life expectancy. Chronic systemic inflammation, shared immunological pathways, and elevated pro-inflammatory cytokines are thought to underlie this association.
View Article and Find Full Text PDFNarrowband-Ultraviolet B Phototherapy for Psoriasis Treatment in Skin of Color: A Systematic Review and Meta-Analysis.
Photodermatol Photoimmunol Photomed
September 2025
Department of Dermatology, University of Miichigan, Ann Arbor, Michigan, USA.
Background: Narrowband-ultraviolet B (NB-UVB) phototherapy is an effective treatment for psoriasis in patients who have failed topical regimens or those who desire to avoid systemic treatment. Despite its regular use in non-white individuals, NB-UVB treatment response for psoriasis in skin of color (SOC) has not been systematically reviewed.
Methods: We conducted a systematic review on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) on all available studies to date assessing NB-UVB for psoriasis treatment in skin of color (SOC) (up to 15 November 2024).